1 1 **PLOS One** 2 3 Full title: Palliative care in the treatment of women with breast cancer: a scoping review protocol 4 5 Short Title: Palliative care in the treatment of women with breast cancer 6 Authors: Romel Jonathan Velasco-Yanez¹, RN, Master student. E-mail: romebarce 95@hotmail.com 7 Ana Fátima Carvalho Fernandes¹, RN, Ph.D. E-mail: afcana@ufc.br 8 Samuel Miranda Mattos², BPEd, Ph.D student. E-mail: profsamuelmattos@gmail.com 9 Thereza Maria Magalhães Moreira², RN, Ph.D. E-mail: thereza.moreira@uece.br 10 Régia Christina Moura Barbosa Castro¹, RN, Ph.D. E-mail: afcana@ufc.br 11 12 Luís Carlos Lopes-Júnior^{3*}, RN, Ph.D. E-mail: regiabarbosa@hotmail.com 13 14 Affiliations: 15 ¹ Department of Nursing, Federal University of Ceará, Fortaleza, Ceará, Brazil ² Graduate Program in Public Health, Ceará State University, Fortaleza, Ceará, Brazil 16 17 ³ Department of Nursing, Federal University of Espírito Santo, Vitória, Espírito Santo, Brazil 18 19 Corresponding author: Dr. Luís Carlos Lopes-Júnior (RN., OCN., MSc., Ph.D.). Adjunct 20 Professor of the Nursing Department at Health Sciences Center, and Graduate Program in Public Health at the Federal University of Espírito Santo (UFES), Av. Marechal Campos, 21 22 1468 – Maruípe, Zip Code: 29.043-900, Vitória, ES, Brazil. E-mail: [lopesjr.lc@gmail.com] 23 Phone: +55(27)99249-7217. ORCID: https://orcid.org/0000-0002-2424-6510 24 25 **Author Contributions** Conceptualization: RJV-Y and AFCF 26 27 Methodology: LCLJ 28 Resources: AFCF 29 Acquisition/interpretation of data for the work: RJV-Y, AFCF, SMM, TMMM, RCMBC 30 and LCLJ **Supervision:** AFCF and LCLJ 31 32 Writing – original draft: RJV-Y, AFCF and LCLJ 33 Writing - review & editing, and approving the final version: RJV-Y, AFCF, SMM, 34 TMMM. RCMBC and LCLJ 35 **Guarantors:** AFCF and LCLJ 36 37 **Competing interests:** The authors have declared that no competing interests exist. 38 **Acknowledgements:** None to declare. 39 40 Patient consent for publication: Not required 41 42 Word Count: 2228 words. 43 Patient consent: Not required. 44 **Provenance and peer review:** Not commissioned; externally peer reviewed.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to quide clinical practice.

45

46

47

48

49 **ABSTRACT**

50

51

52

53

54

55

56

57

58

59

60

61 62

63

64 65

66

67

68 69

70 71

72

73

74

75

76

77

78

79

80

81 82 83

84

85

86

87

88

89

90

91

92

93

94

Introduction: Palliative care is an approach that improves patients' quality of life and their families when they face problems inherent to a life-threatening illness. In the current scenario where breast cancer ranks first among the most common types of cancer in women, research has revealed little control by these patients over the symptoms of the disease and its treatment, resulting in poor quality of life, which should be the focus of attention of palliative care. Thus, the purpose of this study is to map and synthesize the available evidence on palliative care in treating breast cancer women.

Methods: This scoping review protocol was elaborated following the methodological recommendations proposed by the Joanna Briggs Institute (JBI) and the PRISMA Extension for Scoping Reviews (PRISMA-ScR) checklist. All study designs, experimental studies. observational studies, qualitative studies, mixed studies, and reviews reporting the palliative care for breast cancer women, will be considered. The following electronic databases will be searched: MEDLINE (via PubMed), Embase, Cochrane Library, Web of Science, Scopus, JBI Evidence Synthesis, Epistemonikos, CINAHL (via EBSCO), LILACS, and the electronic repository SciELO. In addition, The British Library, Google Scholar, Preprints for Health Sciences [medRXiv], Open Grey, Who Library Database, ProQuest Global Dissertations and Theses, Clinical Trials, gov, and the WHO International Clinical Trials Registry Platform will be searched. No language or date restriction will be applied in the search strategy. Two investigators will independently select studies and perform data extraction and critical appraisal using the using JBI design-specific tolos. A narrative synthesis of the evidence will be carried out and will be grouped and presented in tables and graphic models. Also, a similarity analysis will be performed using IRaMuTeQ software version 0.7 alpha 2, leading to textual categories and themes.

Expected Results: The findings of this review will help to identify the gaps for the design of future primary research on women with breast cancer in palliative care. Ultimately, will position care services, managers, and health professionals in the knowledge of the phenomenon, so that they can implement the best evidence-based palliative care practices and improve the quality of care provided to breast cancer patients.

Open Science Framework Registration: osf.io/5bwq7

Keywords: Women; Breast cancer; Palliative care; Scoping review.

Introduction

Talking about palliative care (PC) today is an interesting challenge due to the complex heterogeneity of conceptions that emerge from this term. However, PC is not a new concept. Saunders [1], the forerunner of the "modern philosophy of hospice," already emphasized in 1978 the importance of PC in the care of patients with serious illnesses, a premise that today, with the increase in life expectancy and scientific progress of medical sciences has become more relevant. The growing incidence-prevalence of chronic-degenerative diseases has prolonged the "death process", making it essential to integrate PC into care process towards the end of life.

It is stand out that only 14% of people who need palliative care receive it worldwide. It is estimated that, annually, 40 million people need PC; 78% of them live in low- and middle-income countries that lack training and awareness of PC among health professionals, a major obstacle in addition to the lack of public and government policies aimed at the implementation of PC at the different levels of health care [2].

Palliative care aims to improve the quality of life (QoL) of patients and their families when facing life-threatening situations, and it is essential to improve the well-being, comfort, and dignity of these individuals [3]. In this sense, PC becomes necessary in the therapeutic approach of people with chronic diseases and, despite the negative or passive connotation of the term, palliative treatment must be eminently active, for example, in patients with advanced cancer, who need surgical and radiotherapy treatments to achieve cancer symptom clusters control [4–6].

Worldwide, an estimated 19.3 million new cancer cases (18.1 million excluding nonmelanoma skin cancer) and almost 10.0 million cancer deaths (9.9 million excluding nonmelanoma skin cancer) occurred in 2020 [7]. Female breast cancer has surpassed lung cancer as the most commonly diagnosed cancer, with an estimated 2.3 million new cases (11.7%) [7]. Thus, breast cancer may be of interest for the development of research in the areas of diagnosis, treatment, disease control, and palliative care.

The diagnosis of breast cancer harms the life of women, who experience feelings of fear and suffering throughout the entire process, from diagnosis to therapeutic and survival stages [8,9]. In this context, PC aims to improve chronic disease patients' and families' QoL, helping alleviate symptoms and maintain disease control, thus achieving a balance between progression and the discomfort caused by the medical treatment [10].

Studies conducted by Kokkone et al. [11] and the updated Clinical Practice Guideline of the American Society of Clinical Oncology [12] recommend that inpatient and outpatient

patients with advanced cancer should receive specific palliative care services, early in the course of the disease, at the same time as active treatment. However, this recommendation is not always met, especially in developing countries with an unmet need for PC [13,14].

Despite the strong degree of recommendation to include PC from diagnosis, recent studies evaluating the QoL in women with breast cancer [8,15–20] have shown a high prevalence of symptoms such as pain, anxiety, fear, cancer-related fatigue, insomnia, dyspnea, and sexual dysfunction, among others. This leads us to think about the current role that PC plays in the treatment of breast cancer, how they are being addressed in this population and their impact on these women's lives.

In addition, it is important to know the role that PC plays in the healthcare of vulnerable populations, in line with the third Objective of Sustainable Development [21]: "To enable everyone to live in good health and promote the well-being of all at all ages". Hence, the purpose of this scoping review is to map and synthesize the available evidence on palliative care in treating breast cancer women. The following specific will guide the review:

- What is the scope of the evidence on guidelines or protocols that direct the delivery of palliative care in women with breast cancer?
- What is the extent of the literature on the QoL benefits for women with breast cancer receiving palliative care?

Materials and methods

Design

This is a scoping review following the methodological recommendations proposed by the Jonna Briggs Institute (JBI) [22] based on the initial definition of the method proposed by Arskey & O'Malley [23] (Figure 1) as well as the PRISMA Extension for Scoping Reviews (PRISMA-ScR) checklist [24]. The protocol was registered in Open Science Framework (Registration number: osf.io/5bwq7).




Figure 1. Steps of the scoping review methodology

Literature review question

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

The Population, Concept, Context (PCC) framework proposed by the Jonna Briggs Institute (JBI) was used for the construction of the research question [22] as follows: P young, adult, and older women, C - palliative care, and C - breast cancer, resulting in the following research question: What is the available evidence on palliative care in the treatment of women with breast cancer?

Inclusion criteria

All studies addressing the variables of the PCC acronym will be included, without restricting the methodological design (e.g., experimental, quasi-experimental, prospective and retrospective cohort, case-control, cross-sectional, case series, individual case reports, descriptive, qualitative, mixed studies, reviews), and no language or publication date restriction. (Figure 2).




Figure 2. Inclusion criteria aligned with the acronym PCC

Figure 2. Inclusion criteria according to acronym PCC.

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

Participants: All studies addressing women, from a young age, will be included, according to the age classification proposed by the WHO: "young age: 25 to 44 years, middle age: 44 to 60 years, elderly age: 60 to 75 years, senile age: 75-90, and long-livers: after 90" [25]. This distinction was made because the highest incidence of breast cancer occurs in women \geq 40 years (26).

Concept: Studies in line with the referential framework of palliative care described by the WHO will be included [2], defined as "an approach that improves the quality of life of patients and their families facing the problems associated with life-threatening illness through the prevention and relief of suffering by means of early identification, assessment. and treatment of pain and other problems, physical, psychosocial, and spiritual".

Context: All studies addressing breast cancer will be included, without restricting the type of cancer or stage, according to the definition proposed by the WHO [27]. "Breast cancer arises in the lining cells (epithelium) of the ducts (85%) or lobules (15%) in the glandular tissue of the breast. Initially, the cancerous growth is confined to the duct or lobule

("in situ"), where it generally causes no symptoms and has minimal potential for spread (metastasis). Over time, these in situ (stage 0) cancers may progress and invade the surrounding breast tissue (invasive breast cancer) then spread to the nearby lymph nodes (regional metastasis) or to other organs in the body (distant metastasis)".

Exclusion criteria

Studies whose participants have breast cancer diagnosed with other pathologies will be excluded. In addition, studies with male patients with breast cancer will also be excluded.

Search strategy

The search strategy will be carried out systematically in eight electronic databases: MEDLINE (Via PubMed), Embase (Excerpta Medica Database), LILACS (Latin American and Caribbean Health Sciences Literature), Cochrane Library, Web of Science, Scopus, JBI Evidence Synthesis, Epistemonikos, CINAHL (Cumulative Index to Nursing and Allied Health Literature via EBSCO), as well as the electronic repository SciELO (Scientific Electronic Library Online). It is emphasized that there will be no date or language restrictions in the search strategy. In addition to the electronic databases mentioned above, other sources will be also searshed including: The British Library, Google Scholar, Preprints for Health Sciences [medRXiv], Open Grey, Who Library Database, ProQuest Global Dissertations, and Theses, ClinicalTrials.gov, and the WHO International Clinical Trials Registry Platform.

Due to the flexibility of including gray literature in scoping reviews [22] and the importance of knowing the role of PC in breast cancer, gray literature will also be included [28], such as clinical practice guidelines, protocols, and information contained in the websites of recognized scientific societies that deal with breast cancer and PC.

In addition, the final reference list from the included primary studies will be manually scanned to find relevant studies. Two researchers will search independently, according to the JBI guidelines [22]. Initially, we will identify the existence of an index of specific subject in each database (with MeSH terms, Emtree, DeCS, and CINAHL headings) and their synonyms (keywords). The search terms will then be combined using the Boolean operators "AND" and "OR" [29,30].

The pilot search strategy elaborated with the help and validation of a librarian combining controlled MeSH descriptors and keywords used in MEDLINE/PubMed is as follows:

P- POPULATION:

#1 ((Women) [MeSH Terms] OR Woman [All Fields] OR Female [MeSH Terms] OR Females [All Fields]))

C- CONCEPT: palliative care

#2 ((Palliative care [MeSH Terms] OR Care, palliative [All Fields] OR Palliative treatment [All Fields] OR Palliative treatments [All Fields] OR Treatment palliative [All Fields] OR Treatments palliative [All Fields] OR Palliative [All Fields] OR Palliative therapy [All Fields] OR Palliative Medicine [MeSH Terms] OR Palliative care medicine [All Fields] OR Palliative supportive care [All Fields] OR Supportive care, palliative [All Fields] OR Supportive care [All Fields] OR Palliative [All Fields] OR Cancer palliative therapy [All Fields]))

#1 AND #2

C- CONCEPT:

#3 ((Breast neoplasms [MeSH Terms] OR Breast neoplasm [All Field] OR Breast tumors [All Fields] OR Breast tumor [All Fields] OR Breast cáncer [All Fields] OR Mammary cancer [MeSH Terms] OR Cancer of breast [All Fields] OR Cancer of the breast [All Fields] OR Mammary carcinoma, human [All Fields]] OR Human mammary carcinomas [All Fields] OR Human mammary neoplasm [All Fields] OR Human mammary neoplasms [MeSH Terms] OR Breast carcinoma [All Fields] OR Breast carcinomas [All Fields] OR Breast carcinomas [All Fields] OR Breast malignant neoplasm [All Fields] OR Malignant tumor of breast [All Fields] OR Breast malignant tumors [All Fields] OR Advanced breast cancer [All Fields]))

#3 #1 AND #2

Selection of the sources of evidence

Rayyan Systems Inc. (RAYYAN) software will use in order to manage the sources of evidence [31]. Initially, all the articles from the general search will be deposited in the RAYYAN software. Then, the duplicates will be removed, and a representative sample of the articles will be taken to evaluate the level of concordance and report the degree of agreement between the two reviewers. Cohen's kappa coefficient will be used to estimate the index of agreement between the 2 evaluators in each review phase [32].

After this phase, the articles will be assessed by titles and abstracts by two independent researchers to identify potentially eligible articles, and another reviewer will resolve any uncertainty regarding the inclusion of a study. Two reviewers will independently

examine the full manuscripts that passed the first selection, and a third reviewer will resolve any decision conflict to obtain a definitive list of studies.

Data charting

The data will be extracted through a form designed by a research team member adapted to the data extraction template proposed by the JBI and considering previously published extraction forms [29,33-36]. The information to be extracted includes a) study identification and objectives; b) study population and baseline characteristics; c) study design; d) sample size; e) results; f) main findings; g) clinical and epidemiological significance; h) conclusions, i) implications, and j) limitations. Two independent reviewers will extract the data from the included studies.

Methodological appraisal of included studies

The hierarchy of evidence [37] will classify the selected studies. This classification is divided into seven hierarchical levels, as described in Table 1.

Table 1. Hierarchy of evidence.

Evidence	Study design
level	
I	Evidence from systematic reviews or meta-analyses of randomized controlled
	clinical trials (RCTs)
II	Evidence from a well-designed RCT
III	Evidence from well-designed controlled clinical trials without randomization
IV	Evidence from well-designed case-control, cohort, or cross-sectional studies
V	Evidence from systematic reviews of qualitative and descriptive studies
VI	Evidence from a single descriptive or qualitative study
VII	Evidence from the opinion of authorities or reports of expert committees

Two independent reviewers will assess the methodological quality of the studies using JBI design-specific tools [38]. Disagreements will be addressed by the third reviewer.

Data analysis and Synthesis of results

A flowchart diagram (Figure 3) will describe the entire study selection process [39].




Figure 3. PRISMA flowchart.

A narrative synthesis of the evidence will be carried out, and the primary quantitative data of the included studies will be tabulated. The results will be grouped and presented in tables, and graphic models. Similarity analysis obtained using the IRaMuTeQ software version 0.7 alpha 2 (Interface de R pour les Analyses Multidimensionnelles de Textes et de Questionnaires) will be carried out through textual categories, as appropriate, to define the final themes.

Discussion and dissemination

Palliative care is essential in treating women with breast cancer, not only because it comprehensively addresses their symptoms but also because it improves their quality of life, and its delivery must be initiated from the diagnosis of the disease. The findings of this review will help to identify the gaps for the design of future research on PC in breast cancer. Ultimately, will position care services, managers, and health professionals in the knowledge of the phenomenon, so that they can implement the best evidence-based PC, consequently improving the quality of care provided to breast cancer patients.

As strong points, this scoping review follows all the methodological recommendations proposed by the JBI. An extensive literature search will be conducted in 9 databases 1 electronic repository. A librarian will guide search strategies, and the final version of this protocol was reviewed and approved by a group of 3 specialists: a breast cancer specialist, a PC specialist, and a scoping review specialist.

11

337 References

- 338 1. Saunders C. The philosophy of terminal care. The management of terminal malignant
- 339 disease. 1984;2:232-41.
- 2. Organización Mundial de la Salud. Cuidados paliativos. Cuidados Paliativos. 2020.
- 341 Disponível em: https://www.who.int/es/news-room/fact-sheets/detail/palliative-care
- 342 3. Organización Mundial de la Salud, Organización Panamericana de la Salud.
- 343 Cuidados Paliativos [Internet]. Pan American Health Organization / World Health
- 344 Organization. 2016. Disponível em:
- 345 https://www3.paho.org/hq/index.php?option=com_content&view=article&id=12587:palliativ
- 346 e-care&Itemid=42139&lang=es
- 347 4. Instituto Nacional de Câncer. Cuidados paliativos. INCA Instituto Nacional de
- 348 Câncer. 2018. Disponível em: https://www.inca.gov.br/controle-do-cancer-do-colo-do-
- 349 utero/acoes-de-controle/cuidados-paliativos
- 5. Lopes-Júnior LC, Rosa GS, Pessanha RM, Schuab SIPC, Nunes KZ, Amorim MHC.
- 351 Efficacy of the complementary therapies in the management of cancer pain in palliative care:
- 352 A systematic review. Rev Lat Am Enfermagem. 2020 Sep 30;28:e3377. doi: 10.1590/1518-
- 353 8345.4213.3377.
- 354 6. Lopes-Júnior LC, Tuma MC, Amorim MHC. Psychoneuroimmunology and oncology
- nursing: a theoretical study. Rev Esc Enferm USP. 2021 Sep 10;55:e20210159.
- 356 7. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F.
- 357 Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide
- 358 for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021 May;71(3):209-249. doi:
- 359 10.3322/caac.21660.
- 360 8. Lopes JV, Bergerot CD, Barbosa LR, Calux NMCT, Elias S, Ashing KT, Domenico
- 361 EBL. Impact of breast cancer and quality of life of women survivors. Rev Bras Enferm. 2018
- 362 Nov-Dec;71(6):2916-2921. doi: 10.1590/0034-7167-2018-0081.
- 363 9. Abrahão CA, Bomfim E, Lopes-Júnior LC, Pereira-da-Silva G. Complementary
- Therapies as a Strategy to Reduce Stress and Stimulate Immunity of Women With Breast
- 365 Cancer. J Evid Based Integr Med. 2019 Jan-Dec;24:2515690X19834169. doi:
- 366 10.1177/2515690X19834169.
- 10. Drageset S, Austrheim G, Ellingsen S. Quality of life of women living with metastatic
- breast cancer and receiving palliative care: A systematic review. Health Care Women Int.
- 369 2021 Sep;42(7-9):1044-1065. doi: 10.1080/07399332.2021.1876063.
- 11. Kokkonen K, Tasmuth T, Lehto JT, Kautiainen H, Elme A, Jääskeläinen AS, Saarto
- T. Cancer Patients' Symptom Burden and Health-related Quality of Life (HRQoL) at Tertiary
- 372 Cancer Center from 2006 to 2013: A Cross-sectional Study. Anticancer Res. 2019
- 373 Jan;39(1):271-277. doi: 10.21873/anticanres.13107.
- 12. Ferrell BR, Temel JS, Temin S, Alesi ER, Balboni TA, Basch EM, et al. Integration of
- Palliative Care Into Standard Oncology Care: American Society of Clinical Oncology Clinical
- 376 Practice Guideline Update. JCO 2017;35(1):96–112. Disponível em:
- 377 https://ascopubs.org/doi/10.1200/JCO.2016.70.1474
- 378 13. Reid EA, Gudina EK, Ayers N, Tigineh W, Azmera YM. Caring for Life-Limiting Illness
- in Ethiopia: A Mixed-Methods Assessment of Outpatient Palliative Care Needs. J Palliat
- 380 Med. 2018 May;21(5):622-630. doi: 10.1089/jpm.2017.0419.
- 381 14. Kaba M, de Fouw M, Deribe KS, Abathun E, Peters AAW, Beltman JJ. Palliative care
- needs and preferences of female patients and their caregivers in Ethiopia: A rapid program

- evaluation in Addis Ababa and Sidama zone. PLoS One. 2021 Apr 22;16(4):e0248738. doi:
- 384 10.1371/journal.pone.0248738.
- 15. Haddou Rahou B, El Rhazi K, Ouasmani F, Nejjari C, Bekkali R, Montazeri A, Mesfioui
- A. Quality of life in Arab women with breast cancer: a review of the literature. Health Qual
- 387 Life Outcomes. 2016 Apr 27;14:64. doi: 10.1186/s12955-016-0468-9.
- 388 16. Villar RR, Fernández SP, Garea CC, Pillado MTS, Barreiro VB, Martín CG. Quality of
- 389 life and anxiety in women with breast cancer before and after treatment. Rev Lat Am
- 390 Enfermagem. 2017 Dec 21;25:e2958. doi: 10.1590/1518-8345.2258.2958.
- 391 17. Ghislain I, Zikos E, Coens C, Quinten C, Balta V, Tryfonidis K, Piccart M, Zardavas
- 392 D, Nagele E, Bjelic-Radisic V, Cardoso F, Sprangers MAG, Velikova G, Bottomley A;
- 393 European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life
- 394 Group; Breast Cancer Group; EORTC Headquarters. Health-related quality of life in locally
- 395 advanced and metastatic breast cancer: methodological and clinical issues in randomised
- 396 controlled trials. Lancet Oncol. 2016 Jul;17(7):e294-e304. doi: 10.1016/S1470-
- 397 2045(16)30099-7.
- 398 18. Mokhtari-Hessari P, Montazeri A. Health-related quality of life in breast cancer
- patients: review of reviews from 2008 to 2018. Health Qual Life Outcomes. 2020 Oct
- 400 12;18(1):338. doi: 10.1186/s12955-020-01591-x.
- 401 19. Salibasic M, Delibegovic S. The Quality of Life and Degree of Depression of Patients
- 402 Suffering from Breast Cancer. Med Arch. 2018 Jun;72(3):202-205. doi:
- 403 10.5455/medarh.2018.72.202-205.
- 404 20. Guerra RL, Dos Reis NB, Corrêa FM, Fernandes MM, Ribeiro Alves Fernandes R,
- 405 Cancela MC, Araújo RM, Crocamo S, Santos M, De Almeida LM. Breast Cancer Quality of
- 406 Life and Health-state Utility at a Brazilian Reference Public Cancer Center. Expert Rev
- 407 Pharmacoecon Outcomes Res. 2020 Apr;20(2):185-191. doi:
- 408 10.1080/14737167.2019.1621752.
- 409 21. Organización Mundial de la Salud. Objetivo 3: Garantizar una vida sana y promover
- 410 el bienestar para todos en todas las edades. Objetivos delDesarrollo Sostenible. 2020.
- Disponível em: https://www.un.org/sustainabledevelopment/es/health/
- 412 22. Aromataris E, Munn Z, Org. JBI Manual for Evidence Synthesis [Internet]. JBI; 2020.
- Disponível em: https://wiki.jbi.global/display/MANUAL
- 414 23. Levac D, Colguhoun H, O'Brien KK. Scoping studies: advancing the methodology.
- 415 Implement Sci. 2010 Sep 20;5:69. doi: 10.1186/1748-5908-5-69. PMID: 20854677; PMCID:
- 416 PMC2954944.
- 417 24. Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, Moher D, Peters
- 418 MDJ, Horsley T, Weeks L, Hempel S, Akl EA, Chang C, McGowan J, Stewart L, Hartling L.
- 419 Aldcroft A, Wilson MG, Garritty C, Lewin S, Godfrey CM, Macdonald MT, Langlois EV,
- 420 Soares-Weiser K, Moriarty J, Clifford T, Tunçalp Ö, Straus SE. PRISMA Extension for
- 421 Scoping Reviews (PRISMA-ScR): Checklist and Explanation. Ann Intern Med. 2018 Oct
- 422 2;169(7):467-473. doi: 10.7326/M18-0850.
- 423 25. Zhaoyang R, Sliwinski MJ, Martire LM, Smyth JM. Age differences in adults' daily
- 424 social interactions: An ecological momentary assessment study. Psychol Aging. 2018
- 425 Jun;33(4):607-618. doi: 10.1037/pag0000242. Epub 2018 Apr 30. PMID: 29708385;
- 426 PMCID: PMC6113687.
- 427 26. Coughlin SS. Epidemiology of Breast Cancer in Women. In: Ahmad A, organizador.
- 428 Breast Cancer Metastasis and Drug Resistance: Challenges and Progress. Cham: Springer

- 429 International Publishing; 2019:9–29. Disponível em: https://doi.org/10.1007/978-3-030-
- 430 20301-6 2
- 431 27. Organización Mundial de la Salud. Cáncer de mama. Cáncer de Mama. 2021.
- Disponível em: https://www.who.int/es/news-room/fact-sheets/detail/breast-cancer
- 433 28. Botelho RG, Oliveira C da C de. Literaturas branca e cinzenta: uma revisão
- 434 conceitual. Ciência da Informação. 2015;44(3). Disponível em:
- 435 http://revista.ibict.br/ciinf/article/view/1804
- 436 29. Lopes-Júnior LC, Sigueira PC, Maciel ELN. School reopening and risks accelerating
- 437 the COVID-19 pandemic: A systematic review and meta-analysis protocol. PLoS One. 2021
- 438 Nov 17;16(11):e0260189. doi: 10.1371/journal.pone.0260189.
- 439 30. Gonçalves CA, Lopes-Júnior LC, Nampo FK, Zilly A, Mayer PCM, Pereira-da-Silva
- 440 G. Safety, efficacy and immunogenicity of therapeutic vaccines in the treatment of patients
- with high-grade cervical intraepithelial neoplasia associated with human papillomavirus: a
- systematic review protocol. BMJ Open. 2019 Jul 17;9(7):e026975. doi: 10.1136/bmjopen-
- 443 2018-026975.
- 444 31. Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan-a web and mobile
- app for systematic reviews. Syst Rev. 2016 Dec 5;5(1):210. doi: 10.1186/s13643-016-0384-
- **4**46 **4**.
- 447 32. McHugh ML. Interrater reliability: the kappa statistic. Biochem Med (Zagreb).
- 448 2012;22(3):276-82. PMID: 23092060; PMCID: PMC3900052.
- 449 33. Lopes-Júnior LC, Bomfim E, Olson K, Neves ET, Silveira DSC, Nunes MDR,
- Nascimento LC, Pereira-da-Silva G, Lima RAG. Effectiveness of hospital clowns for
- 451 symptom management in paediatrics: systematic review of randomised and non-
- 452 randomised controlled trials. BMJ. 2020 Dec 16;371:m4290. doi: 10.1136/bmj.m4290.
- 453 34. Lopes-Júnior LC, Bomfim EO, Nascimento LC, Nunes MD, Pereira-da-Silva G, Lima RA.
- Non-pharmacological interventions to manage fatigue and psychological stress in children
- and adolescents with cancer: an integrative review. Eur J Cancer Care (Engl). 2016
- 456 Nov;25(6):921-935. doi: 10.1111/ecc.12381.
- 457 35. Armstrong R, Hall BJ, Doyle J, Waters E. Cochrane Update. 'Scoping the scope' of a
- 458 cochrane review. J Public Health (Oxf). 2011 Mar;33(1):147-50. doi:
- 459 10.1093/pubmed/fdr015. PMID: 21345890.
- 36. Valaitis R, Martin-Misener R, Wong ST, MacDonald M, Meagher-Stewart D, Austin P,
- 461 Kaczorowski J, O-Mara L, Savage R; Strengthening Primary Health Care through Public
- Health and Primary Care Collaboration Team. Methods, strategies and technologies used
- 463 to conduct a scoping literature review of collaboration between primary care and public
- 464 health. Prim Health Care Res Dev. 2012 Jul;13(3):219-36. doi:
- 465 10.1017/S1463423611000594.
- 466 37. Fineout-Overholt E, Melnyk BM, Stillwell SB, Williamson KM. Evidence-based
- 467 practice step by step: Critical appraisal of the evidence: part I. Am J Nurs. 2010
- 468 Jul;110(7):47-52. doi: 10.1097/01.NAJ.0000383935.22721.9c.38.
- 469 38. Critical Appraisal Tools JBI. 2017. Disponível em http://joannabriggs.org/research/
- 470 critical-appraisal-tools.html

- 39. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The
- 472 PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021
- 473 Mar 29;372:n71. doi: 10.1136/bmj.n71.